LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.49 per share a year ago.
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | George W. LeMaitre CEO | NASDAQ (NMS) Exchange | 525558201 CUSIP |
| US Country | 651 Employees | 20 Nov 2025 Last Dividend | - Last Split | 19 Oct 2006 IPO Date |
LeMaitre Vascular, Inc. is a global company focused on the design, manufacture, and marketing of medical devices and implants for vascular surgery. Initially founded as Vascutech, Inc., the company transitioned to its current name in April 2001. With its beginnings in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular stands as a pioneer in the vascular health sector. It offers a diverse range of products, including devices for blood vessel viewing, blood clot removal, and vascular reconstruction, catering to the needs of surgeons and patients worldwide. The company’s approach combines innovative technology with practical applications in vascular surgery, distributing its products through a direct sales force and a network of distributors.